Summary of AEs by treatment phase
| . | Induction phase (n = 42) . | Consolidation phase (n = 42) . | Follow-up phase (n = 42) . | Overall (N = 42) . |
|---|---|---|---|---|
| Patients with any AE, n (%) | 42 (100.0) | 28 (66.7) | 12 (28.6) | 42 (100.0) |
| Grade 3-4 AE, n (%) | 28 (66.7) | 14 (33.3) | 7 (16.7) | 32 (76.2) |
| Neutropenia | 19 (45.2) | 4 (9.5) | 1 (2.4) | |
| Febrile neutropenia | 5 (11.9) | 1 (2.4) | 0 (0.0) | |
| Anemia | 3 (7.1) | 0 (0.0) | 1 (2.4) | |
| Leukopenia | 2 (4.8) | 0 (0.0) | 0 (0.0) | |
| Fatigue | 2 (4.8) | 0 (0.0) | 0 (0.0) | |
| Lipase increased | 2 (4.8) | 3 (7.1) | 0 (0.0) | |
| Syncope | 1 (2.4) | 2 (4.8) | 0 (0.0) | |
| AE leading to any study treatment discontinuation, n (%) | 6 (14.3) | 9 (21.4) | 0 (0.0) | 15 (35.7) |
| SAE, n (%) | 11 (26.2) | 5 (11.9) | 5 (11.9) | 18 (42.9) |
| . | Induction phase (n = 42) . | Consolidation phase (n = 42) . | Follow-up phase (n = 42) . | Overall (N = 42) . |
|---|---|---|---|---|
| Patients with any AE, n (%) | 42 (100.0) | 28 (66.7) | 12 (28.6) | 42 (100.0) |
| Grade 3-4 AE, n (%) | 28 (66.7) | 14 (33.3) | 7 (16.7) | 32 (76.2) |
| Neutropenia | 19 (45.2) | 4 (9.5) | 1 (2.4) | |
| Febrile neutropenia | 5 (11.9) | 1 (2.4) | 0 (0.0) | |
| Anemia | 3 (7.1) | 0 (0.0) | 1 (2.4) | |
| Leukopenia | 2 (4.8) | 0 (0.0) | 0 (0.0) | |
| Fatigue | 2 (4.8) | 0 (0.0) | 0 (0.0) | |
| Lipase increased | 2 (4.8) | 3 (7.1) | 0 (0.0) | |
| Syncope | 1 (2.4) | 2 (4.8) | 0 (0.0) | |
| AE leading to any study treatment discontinuation, n (%) | 6 (14.3) | 9 (21.4) | 0 (0.0) | 15 (35.7) |
| SAE, n (%) | 11 (26.2) | 5 (11.9) | 5 (11.9) | 18 (42.9) |